PharmaEssentia saw the highest growth of 0.99% in patent filings in May and 0.49% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of PharmaEssentia’s patent filings and grants. Buy the databook here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
PharmaEssentia has been focused on protecting inventions in Spain(ES) with one publication in Q2 2024
The Spain(ES) Patent Office dominates the patent grants with nearly 100% of grants. The Hungary(HU), United States(US), and Spain(ES) patent Office are among the top ten patent offices where PharmaEssentia is filings its patents. Among the top granted patent authorities, PharmaEssentia has 100% of its grants in Spain(ES).
Hanmi Science and Nektar Therapeutics could be the strongest competitors for PharmaEssentia
Patents related to cell & gene therapy and immuno-oncology lead PharmaEssentia's portfolio
PharmaEssentia has the highest number of patents in cell & gene therapy followed by, immuno-oncology and rare diseases. For cell & gene therapy, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Liver cancer related patents lead PharmaEssentia portfolio followed by cardiovascular disease, and liver cirrhosis
PharmaEssentia has highest number of patents in liver cancer followed by cardiovascular disease, liver cirrhosis, liver diseases, and metabolic disorders.
For comprehensive analysis of PharmaEssentia's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

